Matthew Weston
Stock Analyst at UBS
(4.42)
# 1,165
Out of 4,491 analysts
342
Total ratings
74.8%
Success rate
12.1%
Average return
Main Sectors:
Stocks Rated by Matthew Weston
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SWX: GALD Galderma Group AG | Maintained: Buy | CHF 200.00 | $176.55 | +13.28% | 11 | Jul 1, 2026 | |
| ETR: BAYN Bayer Aktiengesellschaft | Maintained: Buy | €52.00 | $50.82 | +2.32% | 21 | Jun 26, 2026 | |
| ETR: MRK Merck KGaA | Maintained: Buy | €150.00 | $141.75 | +5.82% | 35 | Jun 26, 2026 | |
| LON: GSK GSK plc | Maintained: Hold | 1,940p | $2,003.00 | -3.15% | 17 | Jun 15, 2026 | |
| SWX: NOVN Novartis AG | Maintained: Hold | CHF 116.00 | $126.80 | -8.52% | 45 | Jun 8, 2026 | |
| SWX: ROP Roche Holding AG | Maintained: Buy | CHF 384.00 → CHF 376.00 | $339.50 | +10.75% | 55 | May 13, 2026 | |
| LON: 0QIU Novo Nordisk A/S | Maintained: Hold | kr 332.00 | $330.00 | +0.61% | 26 | May 8, 2026 | |
| LON: AZN AstraZeneca PLC | Maintained: Buy | 17,600p | $14,364.00 | +22.53% | 65 | Apr 30, 2026 | |
| EPA: SAN Sanofi | Maintained: Hold | €88.00 | $75.78 | +16.13% | 14 | Apr 24, 2026 | |
| ETR: SRT3 Sartorius Aktiengesellschaft | Maintained: Hold | €240.00 | $232.20 | +3.36% | 28 | Apr 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €220.00 | $179.30 | +22.70% | 15 | Apr 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $125 | $128.86 | n/a | 1 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | CHF 750.00 | $574.40 | n/a | 2 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | €95.00 → €72.00 | $168.40 | n/a | 3 | Feb 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $310 | $49.64 | n/a | 3 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $157.03 | n/a | 1 | Jul 5, 2017 |
Galderma Group AG
Jul 1, 2026
Maintained: Buy
Price Target: CHF 200.00
Current: $176.55
Upside: +13.28%
Bayer Aktiengesellschaft
Jun 26, 2026
Maintained: Buy
Price Target: €52.00
Current: $50.82
Upside: +2.32%
Merck KGaA
Jun 26, 2026
Maintained: Buy
Price Target: €150.00
Current: $141.75
Upside: +5.82%
GSK plc
Jun 15, 2026
Maintained: Hold
Price Target: 1,940p
Current: $2,003.00
Upside: -3.15%
Novartis AG
Jun 8, 2026
Maintained: Hold
Price Target: CHF 116.00
Current: $126.80
Upside: -8.52%
Roche Holding AG
May 13, 2026
Maintained: Buy
Price Target: CHF 384.00 → CHF 376.00
Current: $339.50
Upside: +10.75%
Novo Nordisk A/S
May 8, 2026
Maintained: Hold
Price Target: kr 332.00
Current: $330.00
Upside: +0.61%
AstraZeneca PLC
Apr 30, 2026
Maintained: Buy
Price Target: 17,600p
Current: $14,364.00
Upside: +22.53%
Sanofi
Apr 24, 2026
Maintained: Hold
Price Target: €88.00
Current: $75.78
Upside: +16.13%
Sartorius Aktiengesellschaft
Apr 23, 2026
Maintained: Hold
Price Target: €240.00
Current: $232.20
Upside: +3.36%
Apr 17, 2026
Maintained: Hold
Price Target: €220.00
Current: $179.30
Upside: +22.70%
Nov 1, 2024
Maintained: Buy
Price Target: $125
Current: $128.86
Upside: n/a
Jan 27, 2022
Maintained: Buy
Price Target: CHF 750.00
Current: $574.40
Upside: n/a
Feb 11, 2020
Upgraded: Hold
Price Target: €95.00 → €72.00
Current: $168.40
Upside: n/a
Nov 2, 2018
Maintained: Hold
Price Target: $310
Current: $49.64
Upside: n/a
Jul 5, 2017
Downgraded: Sell
Price Target: n/a
Current: $157.03
Upside: n/a